Stage IIIA Skin Melanoma Completed Phase 2 Trials for Temsirolimus (DB06287)

IndicationStatusPhase
DBCOND0029533 (Stage IIIA Skin Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397982Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant MelanomaTreatment